Given the prevalence of KRAS mutations in pancreatic cancer, we analyzed a panel of cell lines possessing either KrasG12D/TP53 double mutants (FC1242 and mT42D) [21, 22] or KrasG12D mutation alone (6606PDA, 6606I, and 7265PDA) [23]. This evidence concerns the gene KRAS and pancreatic neoplasm.